NMOSD
MCID: NRM008
MIFTS: 33

Neuromyelitis Optica Spectrum Disorder (NMOSD)

Categories: Eye diseases, Immune diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Neuromyelitis Optica Spectrum Disorder

MalaCards integrated aliases for Neuromyelitis Optica Spectrum Disorder:

Name: Neuromyelitis Optica Spectrum Disorder 54
Neuromyelitis Optica 74
Nmosd 54

Classifications:



External Ids:

UMLS 74 C0027873

Summaries for Neuromyelitis Optica Spectrum Disorder

MalaCards based summary : Neuromyelitis Optica Spectrum Disorder, also known as neuromyelitis optica, is related to neuromyelitis optica and multiple sclerosis. An important gene associated with Neuromyelitis Optica Spectrum Disorder is AQP4 (Aquaporin 4). The drugs Mycophenolic acid and Prednisone have been mentioned in the context of this disorder. Affiliated tissues include brain, b cells and spinal cord.

Related Diseases for Neuromyelitis Optica Spectrum Disorder

Diseases in the Neuromyelitis Optica family:

Neuromyelitis Optica Spectrum Disorder

Diseases related to Neuromyelitis Optica Spectrum Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 102)
# Related Disease Score Top Affiliating Genes
1 neuromyelitis optica 11.5
2 multiple sclerosis 10.9
3 optic neuritis 10.7
4 neuritis 10.7
5 myelitis 10.7
6 sjogren syndrome 10.6
7 transverse myelitis 10.6
8 encephalitis 10.5
9 autoimmune disease 1 10.4
10 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.4
11 depression 10.4
12 autoimmune disease 10.4
13 systemic lupus erythematosus 10.4
14 myasthenia gravis 10.4
15 lupus erythematosus 10.4
16 myasthenia gravis congenital 10.4
17 distal trisomy 3p 10.4
18 anxiety 10.3
19 encephalopathy 10.3
20 scleroderma, familial progressive 10.2
21 hepatitis 10.2
22 hepatitis b 10.2
23 lymphoma 10.2
24 apraxia 10.2
25 leukodystrophy 10.2
26 adenocarcinoma 10.2
27 internuclear ophthalmoplegia 10.2
28 influenza 10.2
29 spondyloarthropathy 1 10.1
30 spinocerebellar ataxia 31 10.1
31 esophageal cancer 10.1
32 split-hand/foot malformation 1 10.1
33 anemia, autoimmune hemolytic 10.1
34 galactorrhea 10.1
35 moyamoya disease 1 10.1
36 biotinidase deficiency 10.1
37 ataxia and polyneuropathy, adult-onset 10.1
38 salla disease 10.1
39 lung cancer susceptibility 3 10.1
40 dengue virus 10.1
41 membranous nephropathy 10.1
42 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 10.1
43 metabolic encephalomyopathic crises, recurrent, with rhabdomyolysis, cardiac arrhythmias, and neurodegeneration 10.1
44 arteriovenous fistula 10.1
45 b-cell lymphomas 10.1
46 brain injury 10.1
47 bronchiolitis obliterans 10.1
48 follicular lymphoma 10.1
49 hemolytic anemia 10.1
50 restless legs syndrome 10.1

Graphical network of the top 20 diseases related to Neuromyelitis Optica Spectrum Disorder:



Diseases related to Neuromyelitis Optica Spectrum Disorder

Symptoms & Phenotypes for Neuromyelitis Optica Spectrum Disorder

Drugs & Therapeutics for Neuromyelitis Optica Spectrum Disorder

Drugs for Neuromyelitis Optica Spectrum Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 92)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mycophenolic acid Approved Phase 4 24280-93-1 446541
2
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
3
Mitoxantrone Approved, Investigational Phase 4 65271-80-9 4212
4 Anti-Bacterial Agents Phase 4
5 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
6 Hormones Phase 4,Phase 3,Phase 2,Phase 1
7 Anti-Infective Agents Phase 4
8 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3,Phase 1
9 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
10 Antibiotics, Antitubercular Phase 4
11 Antitubercular Agents Phase 4
12 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1
13 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
14 Analgesics Phase 4
15 Topoisomerase Inhibitors Phase 4
16 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
17
Prednisolone phosphate Approved, Vet_approved Phase 3,Phase 2,Phase 1 302-25-0
18
Prednisolone Approved, Vet_approved Phase 3,Phase 2,Phase 1 50-24-8 5755
19
Methylprednisolone hemisuccinate Approved Phase 3,Phase 2,Phase 1 2921-57-5
20
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2,Phase 1 83-43-2 6741
21
Azathioprine Approved Phase 2, Phase 3,Phase 3 446-86-6 2265
22
rituximab Approved Phase 2, Phase 3,Phase 3,Phase 1 174722-31-7 10201696
23
Mesna Approved, Investigational Phase 2, Phase 3,Phase 1 3375-50-6 598
24
Ifosfamide Approved Phase 2, Phase 3,Phase 1 3778-73-2 3690
25
Cyclophosphamide Approved, Investigational Phase 2, Phase 3,Phase 1 6055-19-2, 50-18-0 2907
26
Lenograstim Approved, Investigational Phase 2, Phase 3,Phase 1 135968-09-1
27
Sargramostim Approved, Investigational Phase 2, Phase 3 123774-72-1, 83869-56-1
28
Prednisolone hemisuccinate Experimental Phase 3,Phase 2,Phase 1 2920-86-7
29 Neuroprotective Agents Phase 3,Phase 2,Phase 1
30 Protective Agents Phase 3,Phase 2,Phase 1
31 Gastrointestinal Agents Phase 3,Phase 2,Phase 1
32 Antiemetics Phase 3,Phase 2,Phase 1
33 Methylprednisolone Acetate Phase 3,Phase 2,Phase 1
34 Prednisolone acetate Phase 3,Phase 2,Phase 1
35 Autonomic Agents Phase 3,Phase 2,Phase 1
36 Immunologic Factors Phase 2, Phase 3,Phase 3,Phase 1
37 Antibodies Phase 3,Phase 2,Phase 1,Not Applicable
38 Immunoglobulins Phase 3,Phase 2,Phase 1,Not Applicable
39 Antimetabolites Phase 2, Phase 3,Phase 3
40 Antineoplastic Agents, Immunological Phase 2, Phase 3,Phase 3,Phase 1
41 Immunosuppressive Agents Phase 2, Phase 3,Phase 3,Phase 1
42 Antimetabolites, Antineoplastic Phase 2, Phase 3,Phase 3
43 Antirheumatic Agents Phase 2, Phase 3,Phase 3,Phase 1
44 Rho(D) Immune Globulin Phase 2, Phase 3,Phase 3
45 Immunoglobulins, Intravenous Phase 2, Phase 3,Phase 3
46 gamma-Globulins Phase 2, Phase 3,Phase 3
47 Immunoglobulin G Phase 3,Phase 2
48
Isophosphamide mustard Phase 2, Phase 3,Phase 1 0
49 polysaccharide-K Phase 2, Phase 3,Phase 1
50 Antineoplastic Agents, Alkylating Phase 2, Phase 3,Phase 1

Interventional clinical trials:

(show top 50) (show all 52)
# Name Status NCT ID Phase Drugs
1 Mycophenolate Mofetil Treatment With Neuromyelitis Optica Spectrum Disorders in Chinese Patients Unknown status NCT02809079 Phase 4 Mycophenolate mofetil;Prednisone
2 Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders Unknown status NCT02021825 Phase 4 Mitoxantrone
3 A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic’s Disease) Completed NCT00304291 Phase 4 Mitoxantrone
4 Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous Methylprednisolone Unknown status NCT00004645 Phase 3
5 Comparison of Clinical Effects of Azathioprine and Rituximab NMO-SD Patients Completed NCT03002038 Phase 2, Phase 3 Azathioprine;Rituximab
6 A Double Blind Trial To Evaluate The Safety And Efficacy Of Eculizumab In Relapsing NMO Patients (PREVENT Study) Completed NCT01892345 Phase 3 Eculizumab
7 A Phase III Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Neuromyelitis Optica Spectrum Disorders Recruiting NCT03330418 Phase 3
8 Autologous Transplant To End NMO Spectrum Disorder Recruiting NCT03829566 Phase 2, Phase 3 Rituximab;Cyclophosphamide;Mesna;rATG;Methylprednisolone;G-CSF
9 Tocilizumab vs Azathioprine in Neuromyelitis Optica Spectrum Disorders Active, not recruiting NCT03350633 Phase 2, Phase 3 Tocilizumab Injection;Azathioprine
10 A Double-masked, Placebo-controlled Study With Open Label Period to Evaluate MEDI-551 in Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders Active, not recruiting NCT02200770 Phase 2, Phase 3
11 An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients Active, not recruiting NCT02003144 Phase 3
12 Efficacy and Safety Study as Add-on Therapy of Satralizumab (SA237) to Treat NMO and NMOSD Active, not recruiting NCT02028884 Phase 3 satralizumab (SA237);Placebo
13 Efficacy and Safety Study as Monotherapy of Satralizumab (SA237) to Treat NMO and NMOSD Active, not recruiting NCT02073279 Phase 3 satralizumab (SA237);Placebo
14 A Multicentre randomiSed Controlled TRial of IntraVEnous Immunoglobulin Versus Standard Therapy for Transverse Myelitis Terminated NCT02398994 Phase 3 Intravenous Methylprednisolone;Intravenous Immunoglobulin
15 Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis Optica Unknown status NCT01364246 Phase 1, Phase 2
16 Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy. Completed NCT01845584 Phase 2 NPB-01
17 Efficacy and Safety of Bortezomib as add-on Treatment in Relapsing Neuromyelitis Optica Spectrum Disorder Completed NCT02893111 Phase 2 Bortezomib
18 Neuromyelitis Optica (NMO) & Cetirizine Completed NCT02865018 Phase 1, Phase 2 cetirizine
19 Autologous Mesenchymal Stem Cells for the Treatment of Neuromyelitis Optica Spectrum Disorders Completed NCT02249676 Phase 2
20 An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica Completed NCT00904826 Phase 1, Phase 2 Eculizumab
21 A Longitudinal Study of ACTEMRA® (Tocilizumab) as Monotherapy in Highly Active NMOSD Completed NCT03062579 Phase 1, Phase 2 Tocilizumab
22 Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch) Completed NCT02166346 Phase 2 Dalfampridine;Placebo
23 Hematopoietic Stem Cell Transplant in Devic's Disease Active, not recruiting NCT00787722 Phase 1, Phase 2 Cyclophosphamide;G-CSF;rATG;Mesna;Rituximab;Methylprednisolone
24 Autologous Hematopoietic Stem Cell Transplant in Neuromyelitis Optica Terminated NCT01339455 Phase 1, Phase 2
25 Pilot Study of alpha1-antitrypsin to Treat Neuromyelitis Optica Relapses Unknown status NCT02087813 Phase 1 Alpha1-antitrypsin;methylprednisolone
26 C1-esterase Inhibitor (Cinryze) for Acute Treatment of Neuromyelitis Optica Exacerbation Completed NCT01759602 Phase 1 C1-esterase inhibitor (Cinryze)
27 Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations Completed NCT01777412 Phase 1 Bevacizumab
28 Safety and Tolerability of Rituximab in Neuromyelitis Optica Completed NCT00501748 Phase 1 Rituximab
29 Central Pain Study for ABX-1431 Completed NCT03138421 Phase 1 ABX-1431 HCl;Placebo
30 Treatment of Multiple Sclerosis and Neuromyelitis Optica With Regulatory Dendritic Cell: Clinical Trial Phase 1 B Recruiting NCT02283671 Phase 1
31 Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses Active, not recruiting NCT02276963 Phase 1 Ublituximab
32 Treatment of Relapsed and/or Refractory AQP4-IgG Seropositive NMOSD by Tandem CAR T Cells Targeting CD19 and CD20 Not yet recruiting NCT03605238 Phase 1
33 Maintenance Plasma Exchange for Neuromyelitis Optica Unknown status NCT01500681
34 Evaluation of Neural Loss in Multiple Sclerosis and Neuromyelitis Optica Using High Resolution Oct Unknown status NCT01024985
35 The Correlation Between AQP-4 Ab and the Visual Function of Patients With Demyelinating ON at Onset Unknown status NCT02886377
36 Quantitation of McArdle's Sign and Evaluation of Specificity for Multiple Sclerosis Completed NCT03122873
37 Pathologic-MRI Findings in Atypical IIDD Completed NCT03121105
38 Multimodel Magnetic Resonance Imaging (MRI)of Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders Recruiting NCT02836327
39 Pediatric NMOSD Observational Study Recruiting NCT03766347
40 The French Cohort and Biobank of Devic's Neuromyelitis Optica and Related Neurological Disorders (NMOSD) (NOMADMUS) Recruiting NCT02850705
41 The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders Recruiting NCT01623076
42 The French Multiple Sclerosis Registry Recruiting NCT02889965
43 Analysis of the Distribution of Regulatory B Cells in Blood of Multiple Sclerosis Patients Recruiting NCT02789670
44 Stem Cell Ophthalmology Treatment Study II Recruiting NCT03011541 Not Applicable
45 Scrambler Trial for Pain in NMOSD Active, not recruiting NCT03452176 Not Applicable
46 Biobank For MS And Other Demyelinating Diseases Active, not recruiting NCT00445367
47 Optical Coherence Tomography and Optic Neuritis (OCTON) Active, not recruiting NCT02573792
48 Clinic Registry Study of Optic Neuromyelitis Spectrum Disease in China Enrolling by invitation NCT03514030
49 Stem Cell Ophthalmology Treatment Study Enrolling by invitation NCT01920867 Not Applicable
50 Clinical Patterns of Neuromyelitis Optica Spectrum Disorders in Assiut University Hospital Not yet recruiting NCT03819413

Search NIH Clinical Center for Neuromyelitis Optica Spectrum Disorder

Genetic Tests for Neuromyelitis Optica Spectrum Disorder

Anatomical Context for Neuromyelitis Optica Spectrum Disorder

MalaCards organs/tissues related to Neuromyelitis Optica Spectrum Disorder:

42
Brain, B Cells, Spinal Cord, T Cells, Lung, Eye, Testes

Publications for Neuromyelitis Optica Spectrum Disorder

Articles related to Neuromyelitis Optica Spectrum Disorder:

(show top 50) (show all 1233)
# Title Authors Year
1
Brain MRI Findings in Pediatric-Onset Neuromyelitis Optica Spectrum Disorder: Challenges in Differentiation from Acute Disseminated Encephalomyelitis. ( 30846436 )
2019
2
Neuromyelitis optica: an elusive cause of dysphagia. ( 30642856 )
2019
3
Limbic encephalitis-like presentation in neuromyelitis optica spectrum disorder: a case report. ( 30835052 )
2019
4
Hypertrophic olivary degeneration mimics relapse in neuromyelitis optica spectrum disorder. ( 30745445 )
2019
5
A case of neuromyelitis optica spectrum disorder following seasonal influenza vaccination. ( 30769255 )
2019
6
Coexistence of Neuromyelitis Optica and Amyotrophic Lateral Sclerosis: A Case Report. ( 30671163 )
2019
7
A Little-Known Brain Imaging Feature in Neuromyelitis Optica Spectrum Disorder: A Leukodystrophy-Like Pattern. ( 30877700 )
2019
8
Can Visual Testing Be Used to Distinguish Neuromyelitis Optica and Multiple Sclerosis? ( 30803517 )
2019
9
Comparison of Ocular Motor Findings Between Neuromyelitis Optica Spectrum Disorder and Multiple Sclerosis Involving the Brainstem and Cerebellum. ( 30827013 )
2019
10
Association of Optic Neuritis with Neuromyelitis Optica Spectrum Disorder and Multiple Sclerosis in Korea. ( 30746915 )
2019
11
Radiomics in multiple sclerosis and neuromyelitis optica spectrum disorder. ( 30770971 )
2019
12
The Role of B Cells and Antibodies in Multiple Sclerosis, Neuromyelitis Optica, and Related Disorders. ( 30800132 )
2019
13
Immunoadsorption or plasma exchange in steroid-refractory multiple sclerosis and neuromyelitis optica. ( 30698295 )
2019
14
Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. ( 30663608 )
2019
15
Peripheral CD19+ B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica/neuromyelitis optica spectrum disorders. ( 30377816 )
2019
16
Plasma exchange: an effective add-on treatment of optic neuritis in neuromyelitis optica spectrum disorders. ( 30825049 )
2019
17
Neuromyelitis optica spectrum disorder coincident with renal clear cell carcinoma: A case report. ( 30732138 )
2019
18
Suspected bacterial meningoencephalomyelitis as the trigger or presentation of neuromyelitis optica spectrum disorder flare. ( 30738276 )
2019
19
Intra-family phenotype variations in familial neuromyelitis optica spectrum disorders. ( 30738281 )
2019
20
The expansion of circulating IL-6 and IL-17-secreting follicular helper T cells is associated with neurological disabilities in neuromyelitis optica spectrum disorders. ( 30769212 )
2019
21
Pontine hemorrhage accompanied by neuromyelitis optica spectrum disorder. ( 30769213 )
2019
22
Foxp3+ regulatory T cells expression in neuromyelitis optica spectrum disorders. ( 30771576 )
2019
23
Clinical course of neuromyelitis optica spectrum disorder in a moroccan cohort. ( 30772672 )
2019
24
Rituximab during pregnancy in neuromyelitis optica: A case report. ( 30800724 )
2019
25
Clinical characteristics of myelin oligodendrocyte glycoprotein antibody neuromyelitis optica spectrum disorder. ( 30825703 )
2019
26
Effectiveness of rituximab in neuromyelitis optica: a meta-analysis. ( 30841862 )
2019
27
Predictive value of conventional MRI parameters in first spinal attacks of neuromyelitis optica spectrum disorder. ( 30843448 )
2019
28
CD55 upregulation in astrocytes by statins as potential therapy for AQP4-IgG seropositive neuromyelitis optica. ( 30851734 )
2019
29
Interleukin-36 alpha levels are elevated in the serum and cerebrospinal fluid of patients with neuromyelitis optica spectrum disorder and correlate with disease activity. ( 30852049 )
2019
30
Neuromyelitis optica spectrum disorder associated with Zika virus infection. ( 30859012 )
2019
31
Neuromyelitis optica spectrum disorders. ( 30872305 )
2019
32
Seronegative neuromyelitis optica spectrum disorder: severe polysymptomatic presentation with successful treatment response. ( 30878968 )
2019
33
Bilateral extensive lesions of the brain in a patient with neuromyelitis optica manifested with seizure and cognitive impairments. ( 30879604 )
2019
34
Quantitative 7T MRI does not detect occult brain damage in neuromyelitis optica. ( 30882018 )
2019
35
Neuromyelitis optica after splenectomy: A secondary autoimmune phenomenon. ( 30884276 )
2019
36
The neuromyelitis optica presentation in HIV seropositive patients. ( 30885372 )
2019
37
Commentary on the manuscript "the neuromyelitis optica presentation in HIV seropositive patients". ( 30885373 )
2019
38
Simulating the Impact of Elevated Levels of Interleukin-6 on the Pharmacokinetics of Various CYP450 Substrates in Patients with Neuromyelitis Optica or Neuromyelitis Optica Spectrum Disorders in Different Ethnic Populations. ( 30887238 )
2019
39
Autonomic dysfunction in people with neuromyelitis optica spectrum disorders. ( 30887872 )
2019
40
Non-target metabolomics profiling of neuromyelitis optica spectrum disorder. ( 30891765 )
2019
41
Neuromyelitis optica spectrum disorders: still evolving and broadening. ( 30893099 )
2019
42
Neuromyelitis Optica with Lesions Involving the Optic Nerves, the Optic Chiasm, and the Optic Tracts. ( 30897583 )
2019
43
So Dramatic They Could Never Be Overlooked: History of Pediatric Neuromyelitis Optica. ( 30898412 )
2019
44
Two Cases of Pediatric AQP4-Antibody Positive Neuromyelitis Optica Spectrum Disorder Successfully Treated with Tocilizumab. ( 30913570 )
2019
45
Noninvasive, Targeted Creation of Neuromyelitis Optica Pathology in AQP4-IgG Seropositive Rats by Pulsed Focused Ultrasound. ( 30500945 )
2019
46
Association of GTF2IRD1-GTF2I polymorphisms with neuromyelitis optica spectrum disorders in Han Chinese patients. ( 30531019 )
2019
47
Myelin oligodendrocyte glycoprotein antibodies in neuromyelitis optica spectrum disorder. ( 30562266 )
2019
48
Erratum: Plasmapheresis for acute attacks in neuromyelitis optica spectrum disorders. ( 30568996 )
2019
49
Pharmacotherapy for Neuromyelitis Optica Spectrum Disorders: Current Management and Future Options. ( 30623348 )
2019
50
Clinical course, treatment responses and outcomes in Chinese paediatric neuromyelitis optica spectrum disorder. ( 30623860 )
2019

Variations for Neuromyelitis Optica Spectrum Disorder

Expression for Neuromyelitis Optica Spectrum Disorder

Search GEO for disease gene expression data for Neuromyelitis Optica Spectrum Disorder.

Pathways for Neuromyelitis Optica Spectrum Disorder

GO Terms for Neuromyelitis Optica Spectrum Disorder

Sources for Neuromyelitis Optica Spectrum Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....